EGFR and colorectal carcinoma: Recent studies underscore the potential of combination therapies involving ICIs and traditional treatments such as chemotherapy and radiotherapy, as well as targeted approaches such as tyrosine kinase inhibitors, anti-angiogenic agents, and EGFR inhibitors, to re-sensitize MSS CRC to immunotherapy.